Physician profile
Moaaz Soliman
NPI 1851824650
$754.05
in general payments reported to CMS, 2019-2025
25 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $188 · 2023: $39.69 · 2024: $194 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $565.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $118.26 | 2022 | |
| Novartis Pharmaceuticals Corporation | $82.34 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $62.71 | 2022-2024 | Tagrisso, Calquence |
| Lilly USA, LLC | $37.81 | 2024-2025 | Jaypirca, Verzenio |
| Janssen Biotech, INC. | $34.54 | 2024-2025 | Erleada, Balversa, Tecvayli |
| Incyte Corporation | $30.76 | 2025 | Monjuvi, Zynyz, Jakafi |
| Pharmaand Gmbh | $29.91 | 2025 | Rubraca |
| Caris Mpi, INC. | $27.47 | 2025 | Mi Cancer Seek |
| Geron Corporation | $26.84 | 2024 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $26.06 | 2025 | Libtayo |
| Eisai INC. | $22.05 | 2025 | |
| Pfizer INC. | $21.81 | 2025 | |
| Genzyme Corporation | $20.36 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.13 | 2024 | Fruzaqla |
| Sobi, INC | $20.05 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $19.90 | 2025 | |
| Merck Sharp & Dohme LLC | $19.24 | 2024 | Keytruda |
| Array Biopharma INC | $19.05 | 2022 | |
| Blueprint Medicines Corporation | $18.49 | 2024 | Ayvakit |
| Verity Pharmaceuticals INC. | $17.58 | 2023 | Trelstar |
| Tolmar, INC. | $17.15 | 2025 | Eligard, Rubraca |
| Ipsen Biopharmaceuticals, INC | $16.72 | 2022 | |
| Daiichi Sankyo INC. | $16.58 | 2024 | Enhertu |
| Jazz Pharmaceuticals INC. | $15.70 | 2025 | |
| Puma Biotechnology, INC. | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moaaz Soliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.